Clinical trials: Dementia Disorders
Alzheimer Disease
Single Ascending Dose Study of SRA-444 in Healthy Subjects
This is a first-in-humans study of SRA-444. This study will provide an initial assessment of the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of SRA-444 (SR formulation) after administration of ascending…
- Trial name
- NCT00452504
- Testing
- SRA-444
- Where
- Netherlands
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Alzheimer Disease
A Study of NH280105 in Healthy Adult Participants
This is a Phase 1, randomized, double-blinded, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) study to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of…
- Trial name
- NCT06870058
- Testing
- NH280105- SAD, NH280105- MAD
- Where
- Australia
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Jiangsu Nhwa Pharmaceutical Co., Ltd.
Huntington Disease
A Repeat Dose Study in Healthy Volunteers Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK356278
The study drug, GSK356278, is a possible new medicine for the treatment of Huntington's disease. Huntington's disease, which is often called HD, is caused by a faulty gene that is passed down through families.
- Trial name
- NCT01573819
- Testing
- GSK356278
- Where
- Netherlands
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Alzheimer Disease
Study Evaluating Lecozotan SR in Mild to Moderate Alzheimer's Disease (AD)
The purpose of this study is determine the safety, tolerability, and efficacy of 3 doses of lecozotan SR in patients with mild to moderate Alzheimer's Disease over 12 weeks.
- Trial name
- NCT00151398
- Testing
- lecozotan SR, Donepezil
- Where
- 56 sites in United States, Argentina and 3 more
- Volunteers
- 229 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Dementia
Study to Evaluate the Effect of Megestrol Acetate in Weight Loss in Dementia Patients
The purpose of this study is to demonstrate the efficacy of megestrol acetate in the gain of body weight in patients with primary or mixed Dementia with a weight loss.
- Trial name
- NCT00503516
- Testing
- Megestrol acetate
- Where
- Spain
- Volunteers
- 39 people
- Sponsor
- Rottapharm Spain
Alzheimer Disease, Late Onset
Tdap and Biomarkers of Alzheimer's Disease
Recently, the Tdap (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis) vaccination was added to the list of immunizations associated with lower incidence of dementia.
- Trial name
- NCT05183516
- Testing
- tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Mindful Diagnostics and Therapeutics, LLC
Alzheimer Disease, Mild Cognitive Impairment
Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease Participants
Phase 1b study to assess the pharmacodynamics, safety, tolerability, and pharmacokinetics of NIO752 in patients with early Alzheimer's disease (AD)
- Trial name
- NCT05469360
- Testing
- NIO752
- Where
- 10 sites in Finland, France and 2 more
- Volunteers
- 38 people
- Sponsor
- Novartis Pharmaceuticals
Alzheimer's Disease
A Phase 2 Study Evaluating The Efficacy And Safety Of PF 04494700 In Mild To Moderate Alzheimer's Disease
The purpose of this study is to evaluate the efficacy and safety of PF 04494700 in participants with mild to moderate Alzheimer's disease.
- Trial name
- NCT00566397
- Testing
- PF-04494700
- Where
- 62 sites in United States
- Volunteers
- 402 people
- Sponsor
- Pfizer
Alzheimer's Disease
Memesto Wearable Repetitive Message and Music Therapy Device Music Therapy Device That Senses and Reduces Agitation in People With AD,
This is a 12-week proof-of-concept study to evaluate the efficacy of Memesto in reducing agitation in persons with Alzheimer's disease and Alzheimer's disease related dementias (AD/ADRD) currently living in a residential care…
- Trial name
- AWARD (NCT06596278)
- Testing
- Memesto
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Edgewater Safety Systems, Inc.
Alzheimer Disease
Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (ALADDIN) VP 104 Study
ALADDIN is a research study to investigate the safety and effectiveness of leuprolide (a hormone drug) to improve the cognitive function and slow the progression of Alzheimer's disease (AD) in men 65 years and older with mild to…
- Trial name
- NCT00076440
- Testing
- Leuprolide acetate
- Where
- 13 sites in United States
- Volunteers
- 90 people
- Sponsor
- Voyager Pharmaceutical Corporation
Alzheimer Disease
Single Dose Escalation Study of CM383 in Healthy Volunteers
This study is a single center, randomized, double-blind, placebo-controlled Phase I clinical study in a single dose escalation to evaluate its safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of CM383…
- Trial name
- NCT06412185
- Testing
- CM383
- Where
- China
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Keymed Biosciences Co.Ltd
Alzheimer's Disease
Safety, Tolerability, and Pharmacokinetics of ABT-354 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
This study will investigate safety, tolerability and pharmacokinetics of ABT-354 in up to 20 male and female subjects, between 55 to 90 years of age with mild to moderate Alzheimer's disease on stable doses of…
- Trial name
- NCT01908010
- Testing
- ABT-354
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- AbbVie
Alzheimer's Disease
A Bioequivalence Study of Corplex™ Donepezil Transdermal Delivery System Compared to Aricept®
A study to assess the steady-state bioequivalence of once-weekly Corplex™ Donepezil 10 mg Transdermal Delivery System (TDS) compared to daily administration of Aricept®
- Trial name
- NCT03259958
- Testing
- Donepezil TDS, Aricept
- Where
- United States
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- Corium, Inc.
Alzheimer's Disease
The Efficacy of Galantamine Treatment on Attention in Patients With Alzheimer's Disease
This study will examine whether the administration of galantamine is effective for improvement of attention and more effective for patients with serious disturbance of attention by administering galantamine to patients with…
- Trial name
- NCT01054976
- Testing
- Galantamine
- Volunteers
- 99 people
- Sponsor
- Janssen Korea, Ltd., Korea
Alzheimer's Disease
A Study to Assess Regional Cerebral Blood Flow as an Alzheimer's Disease Biomarker Compared to Positron Emission Tomography in Patients With Mild-to-Moderate Alzheimer's Disease and Cognitively Normal Elderly Subjects (Study MK-0000-068)(COMPLETED)
The aim of the study is to determine if regional cerebral blood flow, measured by dynamic arterial spin labeling (dASL), can be a biomarker for stage of Alzheimer's disease.
- Trial name
- NCT00757939
- Testing
- MRI, FDG-PET
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Alzheimer Disease
Neuro RX Gamma - Pivotal Phase
The active Neuro RX Gamma device uses non-invasive near-infrared energy delivered to the brain with the intention to improve cognitive functioning and quality of life in patients with moderate to severe Alzheimer's Disease.
- Trial name
- NCT03484143
- Testing
- Active Neuro RX Gamma device
- Where
- 9 sites in United States, Canada
- Volunteers
- 228 people
- Sponsor
- Vielight Inc.
Alzheimer Disease, Vascular Dementia
A Study of the Safety and Effectiveness of Galantamine Versus Placebo in the Treatment of Patients With Vascular Dementia or Mixed Dementia
The purpose of this study is to evaluate the safety and efficacy of galantamine (a drug for treating dementia) compared to placebo in the treatment of patients with dementia related to cerebrovascular disease (vascular dementia)…
- Trial name
- NCT00261573
- Testing
- galantamine hydrobromide
- Volunteers
- 593 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Alzheimer Disease, Mild Cognitive Impairment
Quality Improvement PrecivityAD Clinician Survey (QUIP I)
There is an important unmet need for timely, non-invasive, and low-burden evaluation of patients presenting with mild cognitive impairment (MCI) and early dementia.
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Dementia, Cognitive Decline
- Trial name
- QUIP I (NCT05477056)
- Testing
- PrecivityAD blood test
- Where
- United States
- Volunteers
- 366 people
- Sponsor
- C2N Diagnostics
Dementia of Alzheimer's Type
A Dose Titration Study of CPC-201 in Patients With Dementia of Alzheimer's Type
This is a Phase II, ascending dose study of CPC-201 in patients with dementia of Alzheimer's type to determine the optimal dose titration schedule.
- Trial name
- CPC-12 (NCT02549196)
- Testing
- Donepezil, Solifenacin
- Where
- 4 sites in United States
- Volunteers
- 28 people
- Sponsor
- Chase Pharmaceuticals Corporation, an affiliate of Allergan plc
Parkinson Disease, Dementia
A Study to Evaluate ENT-01 for the Treatment of Parkinson's Disease Dementia
This study will be conducted as a multi-center, open label study in the US. There will be 40 patient to receive the active investigational product.
- Trial name
- NCT03938922
- Testing
- Active Investigational Treatment ENT-01
- Where
- 3 sites in United States
- Sponsor
- Enterin Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.